[Taurine supplementation in cystic fibrosis (CF): effect on vitamin E absorption kinetics].
Oral vitamin E (Vit.E) bioavailability is reduced in CF patients especially in case of malnourishment. Both exocrine pancreatic insufficiency and an altered bile acid composition showing an elevated glycine taurine ratio of conjugated bile acids which is due to excessive loss of bile acids in the stools may contribute to this observation. Because taurine supplementation reduces the glycine/taurine ratio of bile acids in duodenal juice of CF-patients it was the objective of this study to evaluate the effect of taurine supplementation on Vit.E absorption kinetics. Oral Vit.E tolerance tests (50 mg/kg) were performed before and after 3 months of taurine supplementation (30 mg/kg/day) in 11 CF patients (ages 7 to 22 years) under fasting conditions. Bodyweight and or weight for height of all patients were below the 25th percentile. Doses of all medications except antibiotics were kept unchanged during the study. Any additional Vit.E supplementation was stopped 14 days prior to each test. Serum Vit.E levels were measured over a 24 hour period. Determination of serum Vit.E concentrations was performed with a HPLC fluorescence technique. The glycine/taurine ratio in serum served as compliance parameter and dropped in all but one patients. Baseline Vit.E concentrations and serum Vit.E/total lipids ratios in serum considered as parameters of the Vit.E status increased significantly. Both the maximal Vit.E concentrations in serum and the areas under the oral absorption curves showed a significant increase with taurine supplementation. This study shows that the Vit.E status of malnourished CF patients can be improved with taurine supplementation due to improved Vit.E absorption kinetics.(ABSTRACT TRUNCATED AT 250 WORDS)
Skopnik
H
H
Kinderklinik, RWTH Aachen.
Kusenbach
G
G
Bergt
U
U
Friedrichs
F
F
Stuhlsatz
H
H
Döhmen
H
H
Heimann
G
G
D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D003550:Cystic Fibrosis / Q000097:blood / Q000628:therapy*; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology; D008297:Male; D013654:Taurine / Q000008:administration & dosage*; D014810:Vitamin E / Q000008:administration & dosage / Q000097:blood*; D014811:Vitamin E Deficiency / Q000097:blood / Q000628:therapy*
D014810:Vitamin E; D013654:Taurine